Browse News

Found 377 articles

• InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

  5/11/2023

  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial and operating results for the three months ended March 31, 2023, and provided a business update.

• KaliVir Immunotherapeutics Appoints Viral Immunotherapy Researcher Grant McFadden, Ph.D., to its Board of Directors

  5/10/2023

  KaliVir Immunotherapeutics, Inc. today announced the appointment of Grant McFadden , Ph.D., to its Board of Directors.

• IMV Receives NASDAQ Delisting Notice

  5/8/2023

  IMV Inc. announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110 and IM-5101-1, has in exercising its discretion determined to delist the Company's common shares as a result of the Company's announcement on May 1, 2023 that the Nova Scotia Supreme Court had issued an initial order granting the Company and its subsidiaries protection under the Companies’ Creditors Arrangement Act.

• IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors

  5/1/2023

  IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is pleased to announce the appointment of Jeremy Graff, Ph.D., to its Board of Directors.

• InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients

  4/4/2023

  InflaRx N.V. (Nasdaq: IFRX) today announced that Gohibic (vilobelimab), a first-in-class monoclonal anti-human complement factor C5a antibody, has been granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of coronavirus disease 19 (COVID-19) in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO).

• Inspira™ Technologies Reports Fourth Quarter 2022 and Full Year Financial Results

  4/4/2023

   Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies, a company aiming to revolutionize acute respiratory care, announced its financial results for the fourth quarter and year ended December 31, 2022.

• Imvax Announces First Patient Dosed in Phase 2b Trial of IGV-001 for Glioblastoma

  3/27/2023

  Imvax, Inc. today announced dosing of the first patient in the company’s randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in patients with newly diagnosed glioblastoma (ndGBM).

• IMV Inc. Announces Changes to Its Board of Directors

  3/27/2023

  IMV Inc., a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, announced changes to its board of directors as Shermaine Tilley, Ph.D., MBA has resigned from the Board of Directors of the Company, effective immediately.

• IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results

  3/16/2023

  IMV Inc. today announced alongside the release of its fourth quarter and annual results that it has engaged Stonegate Healthcare Partners, L.L.C (“Stonegate”) to explore strategic alternatives following a review of its business.

• IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023

  3/9/2023

  IMV Inc. today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company’s 2022 fourth quarter and fiscal year-end financial and operational results.

• Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients

  2/21/2023

  Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive data from three retrospective real-world studies which demonstrated that initiation of Veklury® (remdesivir) within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity.

• IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial

  2/13/2023

  IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”) today announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S (“MVP-S”), in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma (“r/r DLBCL”).

• Hologic Announces Financial Results for First Quarter of Fiscal 2023

  2/1/2023

  Hologic, Inc. announced the Company’s financial results for the fiscal first quarter ended December 31, 2022.

• Accuray Reports Fiscal 2023 Second Quarter Financial Results

  2/1/2023

  Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter of fiscal 2023 ended December 31, 2022.

• IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S

  1/8/2023

  IMV Inc., a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, outlined its planned 2023 milestones to advance the clinical development of its lead therapeutic, maveropepimut-S.

• 

  BioSpace Layoff Tracker 2022: Axcella Therapeutics, TherapeuticsMD, Instil Bio and More Cull Staff

  12/15/2022

  The layoffs trend in the life sciences industry is continuing into the final months of 2022. See inside for details on which companies are reducing staff to increase cash flow.

• IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL

  12/15/2022

  IMV Inc. today announced positive initial patient data from the VITALIZE Phase 2B trial evaluating its lead DPX product, MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma (“r/r DLBCL”) who received at least three previous lines of treatment.

• IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split

  12/13/2022

  IMV Inc. (the “Corporation” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced that its common shares commence trading post consolidation today.

• IMV Shareholders Approve Reverse Stock Split at 88%

  12/7/2022

  IMV Inc. announced that at the special meeting of shareholders held on December 7, 2022, the share consolidation as described in the management information circular filed on October 28, 2022 was approved by the shareholders at 87.87% of the shares voted and that its board of directors has approved a 1-for-10 reverse stock split of IMV’s common shares immediately thereafter.

• Hologic Ranked #1 for Mammography System Performance and Customer Satisfaction for 10th Consecutive Year

  12/1/2022

  Hologic Ranked #1 for Mammography System Performance and Customer Satisfaction for 10th Consecutive Year.